Kidney stone disease affects 1 - 20% of the general population. At present, the diagnosis of a stone is done using radiography method when noticeable symptoms appeared. We developed a non-invasive quantitative assay for urinary THP, namely ELISA; whereby our previous study and other reports had shown the usefulness of THP as biomarker for kidney stone disease. Since urine is biological fluid that is easily obtainable, this method could be used as a screening assay for kidney stone prior to confirmation with radiography. The ELISA gave assay linearity r(2) > 0.999 within the range of 109 ng/mL to 945 ng/mL THP. Assay precisions were < 4% (C.V.) for repeatability and < 5% (C.V.) for reproducibility. Assay accuracy range from 97.7% to 101.2% at the various THP concentrations tested. Assay specificity and sensitivity were 80% and 86%, respectively. The cut-off points at P < 0.05 were 37.0 and 41.2 mug/mL for male and female, respectively. The assay is cost effective and rapid whereby the cost for assaying each urine sample in duplicate is approximately USD0.35 and within 5 hours, 37 samples can be assayed alongside full range of standards and 3 QC samples in each plate. Furthermore, sample preparation is relatively easy where urine sample was diluted 10 times in TEA buffer. The usability of the ELISA method for diagnosis of kidney stone disease is evaluated with 117 healthy subjects and 58 stone formers.
Kidney stone disease affects 1 - 20% of the general population. At present, the diagnosis of a stone is done using radiography method when noticeable symptoms appeared. We developed a non-invasive quantitative assay for urinary THP, namely ELISA; whereby our previous study and other reports had shown the usefulness of THP as biomarker for kidney stone disease. Since urine is biological fluid that is easily obtainable, this method could be used as a screening assay for kidney stone prior to confirmation with radiography. The ELISA gave assay linearity r(2) > 0.999 within the range of 109 ng/mL to 945 ng/mL THP. Assay precisions were < 4% (C.V.) for repeatability and < 5% (C.V.) for reproducibility. Assay accuracy range from 97.7% to 101.2% at the various THP concentrations tested. Assay specificity and sensitivity were 80% and 86%, respectively. The cut-off points at P < 0.05 were 37.0 and 41.2 mug/mL for male and female, respectively. The assay is cost effective and rapid whereby the cost for assaying each urine sample in duplicate is approximately USD0.35 and within 5 hours, 37 samples can be assayed alongside full range of standards and 3 QC samples in each plate. Furthermore, sample preparation is relatively easy where urine sample was diluted 10 times in TEA buffer. The usability of the ELISA method for diagnosis of kidney stone disease is evaluated with 117 healthy subjects and 58 stone formers.
Entities:
Keywords:
ELISA; Kidney stone disease; Screening assay; Tamm-Horsfall protein
Kidney stone disease affects 1 - 20% of the general population. The lifetime chance of an
individual forming a kidney stone is 10 - 15% with the peak age of onset between 20 and 30 years
old 1. The risk of recurrence is 74% within 10 years for
first-time stone formers 2. Therefore, a rapid and
reliable screening assay for kidney stones is highly desirable. In 1950, Tamm and Horsfall
discovered a glycoprotein in urine that was named the Tamm Horsfall Glycoprotein (THP). THP is
the most abundant protein present in the urine of healthy subjects 3. It is secreted by the thick ascending limb of the loop of Henle 4, 5. THP is inserted
into the luminal cell surface by a glycosyl-phosphatidylinositol (GPI)-anchor and then excreted
in urine at a rate of 50 - 100 mg/day 6, 7. It is a monomeric glycoprotein of ~ 85 kDa with
~30% carbohydrate moiety that is heavily glycosylated by polyantennary sialated
N-linked glycans 8, 9. Sialic acid plays an important role in maintaining THP function during kidney stone
formation 10. THP has a strong tendency to forming
macroaggregates of several million Daltons.THP excretion decreases in stone formers and therefore it was proposed as a potential
biomarker for kidney stone disease 11, 12. Hess et al.
13 described THP as the major inhibitor to calcium
oxalate crystal aggregation in the urine of healthy individuals. However, other reports showed
that stone formers excreted defective urinary THP that devoid of sialic acid with a diminished
effect on inhibiting stone formation 10, 13. A number of assays have been developed to detect THP
includes electroimmunodiffusion, gel electrophoresis, radioimmunoassay and enzyme-linked
immunosorbent assays (ELISA). THP quantification has been limited by relatively insensitive
assays and laborious pretreatment of urine sample i.e. dialysis, gel filtration,
ultracentrifugation, freezing, incubation with detergents and pH adjustment 14. Most of the assays require freezing of the urine for 24
hours followed by dilution in water or buffer at 1:20 to 1:100 before analysis in order to keep
the THP soluble for quantification 11, 12, 14.We developed an ELISA method for quantifying urinary THP. Wheat germ from Tirticum
vulgaris (WGA) that specific to THP 15 was used
to coat microtiter plates for capturing of urinary THP. WGA is a type of lectin that is specific
to the receptor of THP 15. WGA binds specifically to the
di N-acetylglucosamine and sialic acid on the receptor of THP 15 but bind weakly to human chorionic gonadotropin that was
excreted abundantly in urine of pregnant women 16. The
captured THP was recognized by an anti-THP antibody and the Ab-Ag complexes were then recaptured
by a secondary antibody tagged with horseradish peroxidase (HRP), the amount of THP was
quantified based on the intensity of the color reaction developed between the HRP and its
substrate. Its reliability as screening assay for kidney stone disease is determined.
Methods
Urine specimen collection
Urine samples were collected from kidney stonepatients provided by the Urology Clinic,
General Hospital, Pulau Pinang and Lam Wah Ee Hospital, Pulau Pinang, Malaysia. Two cohorts
were recruited in this study i.e. 58 stone formers (34 male, 24 female) age range from 28
– 74 years and 117 healthy subjects (41 male, 76 female) age range from 20
– 86 years. The stone formers comprise 39 staghorn calculi (23 male, 16 female) and
19 acute renal calculi (11 male, 8 female). All the stone formers were confirmed by radiography
using Plain Abdominal Radiography (KUB) and/or Intravenous Urography (IVU) and they were
afflicted by partial obstruction and non obstruction kidney stones. They have not been treated
by surgery or medication. Healthy subjects had no previous history of kidney stones or other
nephrolithiasic related diseases included staffs and students of the School of Pharmaceutical
Sciences, USM and nurses from the nursing institute of Lam Wah Ee Hospital, Penang. The
exclusion criterion for urine is a urinary creatinine concentration < 2.00 mmol/L or
>19.00 mmol/L, normal range is 2.20 – 19.00 mmol/L based on the Cayman
Chemical Creatinine Assay. Aliquots urine samples were stored at -20oC prior to the
assay.
Urinary Creatinine Assay
Creatinine assay was carried out according to Cayman Chemical Creatinine Assay (Cayman
Chemical Company, UK). The assay relies on Jaffe's reaction, wherein a yellow or orange color
is formed when the metabolites are treated with alkaline picrate 17. The color derived from the creatinine is destroyed at acidic pH. The
difference in color intensity measured at OD495 before and after acidification is
proportional to the creatinine concentration 17. A
creatinine standard curve was constructed for urine creatinine concentration determination.
Materials for ELISA
Capture material used for coating was WGA, a type of lectin from Triticum
vulgaris (Sigma) and was purified by affinity chromatography. The primary antibody was
a polyclonal anti-THP antibody (Biomedical Technologies Inc, USA) raised in rabbit and was
claimed to have no significant cross reaction with other proteins by manufacturer. The
secondary antibody was goat anti-rabbit IgG (H+L) horseradish peroxidase conjugate (BioRad).
Substrate was TMB (3,3',5,5' Tetramethylbenzine, 1 mg) (Sigma). TMB substrate solution was
freshly prepared by dissolving a tablet of TMB in 1 mL of dimethyl sulfoxide (DMSO) (Sigma) and
added to 9 mL of 0.05 M phosphate-citrate buffer, pH 5.0. A volume of 2 μL 30%
H2O2 was added to 10 mL of substrate solution.
Preparation of Standards and QC Materials
The standard THP was prepared from pooled normal urines using salt precipitation (1mL urine :
0.27g ammonium sulphate) and calibrated against commercial THP (Biomedical Technology, Inc., 1
μg/μL). The standard had a concentration of 945 ng/mL THP and was serial
diluted to produce solutions with THP concentrations of 417, 236, 165, 123 and 109 ng/mL. The
standards were used to construct standard curves for the assay. For long term storage, the
standards were lyophilized, stored at -20oC and re-suspended in TEA buffer (0.5%
Triton X-100, 20 mM EDTA, pH 7.5) before use. The lyophilized standards were stable for at
least 6 months. In addition, three quality control (QC) samples at THP concentrations 908, 538
and 123 ng/mL were prepared in TEA buffer and labeled QC1, QC2 and QC3, respectively. The QC
samples were aliquoted in microcentrifuge tubes at 300 μL/tube. For long term storage,
the QC samples were lyophilized, stored at -20oC and re-suspended in TEA buffer
before use.
Coating of Microtiter Plate
Each well on the 96-wells microtiter plate (Maxisorp™, Nunc) was coated with 100
μL of 10 μg/mL lectin WGA in coating buffer [5.0 mM
Na2CO3, 34.9 mM NaHCO3, 0.02% (v/v) NaN3, pH 9.6].
The plates were covered with parafilm and incubated at 4oC overnight with shaking
(100 rpm) on an orbital shaker (Protech). The plates were washed five times with freshly
prepared washing buffer (0.1% Tween 20 in 10 mM phosphate buffer saline (PBS) pH 7.2 for 5 min
each. The unoccupied sites on the microtiter plates were blocked with 200 μL blocking
buffer (3% BSA in 10 mM PBS, pH 7.2) and incubated at room temperature for 2 hours with a slow
rotation (50 rpm) on the orbital shaker. The plate was washed five times with washing buffer
for 5 min each wash and dried in an oven at 37oC for 3 hours or until thoroughly
dried. Finally, the plates were cooled to room temperature and sealed with an adhesive plate
seal, wrapped in aluminum foil and stored at 4oC.
ELISA Screening Procedure for THP Measurement
WGA coated plates were brought to room temperature before use. The standards and QC samples
were vortexed gently and added at 100 μL/well into the coated microtiter plate wells.
The frozen samples were stabilized at room temperature and diluted 1:10 in TEA buffer. Urine
samples and standards (109 – 945 ng/mL) were run in duplicate, and QC samples (908
ng/mL, 538 ng/mL and 123 ng/mL) were run in triplicate. TEA buffer was used as blank. After 1
hour incubation at 37oC, the plates were washed five times (rotation, 50 rpm) with
300 μL freshly prepared wash buffer (0.1% Tween 20 in 10 mM PBS, pH 7.2). The plates
were placed top down on absorbent paper to remove residual buffer. Hundred microliter of
1:10,000 dilution anti-THP antibody in antibody diluent buffer (2% BSA, 0.1% Tween 20, 0.02%
NaN3 in 10 mM PBS, pH 7.2) was dispensed in each well and the plates were incubated
at 37oC for 1 hour. The plates were washed five times (rotation, 50 rpm) with 300
μL of freshly prepared wash buffer and the residual buffer was removed on absorbent
paper. The plates were incubated at 37oC for 1 hour after adding the same volume of
goat anti-rabbit IgG (H+L) horseradish peroxidase conjugate diluted 1:3,000 in antibody
diluent. The plates were washed five times (rotation, 50 rpm) with 300 μL of freshly
prepared wash buffer and residual buffer was removed on absorbent paper.Colour was developed by adding 100 μL of TMB substrate solution to each well. The
plates were incubated on orbital shaker (100 rpm) for 15 min at room temperature in the dark.
The reaction was stopped by adding 100 μL of 4 M H2SO4 to each
well. OD450 and OD620 (Thermo Labsystems Multikan Ascent, Finland) were
read immediately. Urinary THP concentration was determined by referring to the standard
curve.
SDS-PAGE for THP Measurement
The aliquot urine (1 mL) was thawed to room temperature and then added with 0.27 g ammonium
sulphate, (NH4)2SO4. After vortex-mixing for 2 minute, the
urine was centrifuged at 10,000 rpm for 20 minutes at 20oC and the supernatant
decanted. The pellet was collected and dissolved in 80 μL of solubilizing buffer [10
mM Tris, 1 mM EDTA, 1% (w/v) SDS, pH 8.8] and vortex-mixed gently for 2 minutes. The mixture
was then added with 20 μL reducing sample buffer, vortex-mixed and heat at
100oC for 10 minutes. After the mixture cool to room temperature, 10 μL of
the mixture was loaded into each well of mini-slab gel. One microliter of the commercial THP
standard (1 μg/μL) was loaded in separated well alongside the samples.
Electrophoresis system used for quantification of THP was mini-slab gel (Protean 3, BioRad)
composed of 4% stacking gel and 10% resolving gel with a gel thickness of 0.75 mm and gel size
8 x 7 cm. The electrophoresis run was at 200 volt for 50 minutes. The relative intensity of the
bands was analyzed using Quantity One 1-D software of VersaDoc Imaging System (BioRad).
Assay Validation
Urine samples from 117 healthy subjects and 58 stone formers were assayed using a reference
method namely SDS-PAGE, where the intensity of THP bands was quantify relatively to commercial
THP at 1 μg/μL concentration. Using SDS-PAGE as the reference method, we
defined true positive (TP) as urine with THP concentration below the cut-off value set when
measured with both ELISA and SDS-PAGE methods while true negative (TN) as urine with THP
concentration above the cut-off value set when measured with both ELISA and SDS-PAGE methods.
In contrary, false positive (FP) were urine with THP concentration above cut-off value with
SDS-PAGE but below cut-off value with ELISA and vice-versa with false negative (FN) urine.
Sensitivity is calculated as TP/ (TP + FN) whereas specificity is TN/ (TN + FP) 18; the results of both calculations are expressed as
percentages.Precision of the assay included repeatability and reproducibility 18. The repeatability (within day precision) was calculated by the
coefficient of variation (C.V.) for each set of the QC materials that were run on the same day,
whereas reproducibility (between day precision) was calculated from the average of the within
assay precision of each QC materials analyzed in three runs at different day. Assay accuracy
was percentage of the average concentration of standard THP as compared to the reported
concentration of the commercial THP.
Data analysis
Data was analysed by using the Statistical Package for Social Sciences (SPSS, version 15.0).
For the correlation studies, Pearson correlation coefficient was employed and the level of
significance was set to alpha = 0.01. Student's t-test was used to determine statistical
significance between cohort groups (alpha = 0.05). Chi-square test was applied for correlation
analysis between ELISA method and the reference method, SDS-PAGE.
Results
WGA coated mircotiter plates were prepared in batch-wise and stored at 4˚C. The
plates were brought to room temperature before use. The optimum plate coating concentration for
WGA was tested by coating the plate with a series of WGA concentration range from 1 –
100 μg/mL. The coated plates were then tested with non-diluted and a range of diluted
urine from 1:5 to 1:100 dilution (Figure 1). At 1:10 urine
dilution, the optimum WGA concentration for plate coating was found to be 10 μg/mL,
where binding of urinary THP to WGA was a linear function from 1 – 10 μg/mL
WGA, increasing in WGA concentration after 10 μg/mL does not improve the OD of the
assay. Bovineserum albumin (BSA) was used to block the non-lectin binding sites on the plate
since THP does not bind to BSA 19. The WGA microtiter
plates were sealed and stored at 4oC where they were stable for at least 6 weeks.
Aggregation of THP results in reduced detection of the glycoprotein, optimum urine dilution with
maximum disaggregation of THP occurring at 1:10 dilution (Figure 1). Increasing the urine dilution beyond this point reduced the detection of THP. The
optimal primary and secondary antibody dilutions were found at 1:10,000 and 1:3,000,
respectively (Figure 2).
Figure 1
Determination of the optimal concentration of WGA for coating onto microtiter plate. A
series of diluted WGA from 1 - 100 μg/mL were investigated at a serial diluted urine
(1:5, 1:10, 1:20, 1:40, 1:80, 1:100) and non-diluted urine. The anti-THP dilution and
secondary HRP conjugate dilution were 1:10,000 and 1:3,000, respectively. The optimum WGA
coating concentration was 10 μg/mL for urine diluted at 1:10.
Figure 2
Determination of the optimal anti-THP dilution and secondary antibody dilution for THP
measurement. A serial dilution of anti-THP from 1:2,500 – 1:280,000 in antibody
diluent were evaluated in three different dilution factor of secondary antibody that were
1:1,000, 1:3,000 and 1:8,000 diluted in same buffer, respectively. The microtiter plate was
coated with 10 μg/mL WGA.
We validated the ELISA based on assay linearity, accuracy, repeatability and reproducibility.
The assay had a linearity of r2 > 0.999 for the THP concentration range from
109 ng/mL to 945 ng/mL. The assay accuracy range from 97.7% to 101.2% over the range of THP
concentrations from 109 ng/mL to 945 ng/mL (Table 1). The
precision (C.V.) of each QC samples in triplicates was consistently < 10% (Table 2). Assay repeatability was < 4% C.V. and assay
reproducibility was < 5% C.V. as measured by using the three QC samples (Table 2).
Table 1
Accuracy of the assay
Commercial THP concentration (ng/mL)
standard THP concentration (ng/mL) (n=3)
Mean standard THP concentration (ng/mL)
Standard Deviation (SD)
Coefficient of Variation (C.V.)
Accuracy
1
2
3
945.67
942.38
943.47
943.32
943.06
0.59
0.06
99.7%
417.50
428.14
427.55
423.10
426.26
2.76
0.65
102.1%
236.33
232.68
229.83
239.00
233.84
4.69
2.01
99.0%
165.50
163.98
156.43
164.45
161.62
4.50
2.79
97.7%
123.33
125.16
128.67
120.76
124.86
3.97
3.18
101.2%
109.33
105.33
111.70
107.04
108.02
3.30
3.05
98.8%
Table 2
The repeatability and precision of the assay. The measurements of QC materials were carried
out over 3 days.
Repeatability (within day precision)
OD reading
THP concentration (μg/mL)
QC 1
QC 2
QC 3
1
905.33
561.20
126.83
2
851.13
540.94
121.57
3
921.14
513.05
122.10
4
855.34
556.39
123.00
5
816.35
538.13
129.57
6
816.02
513.45
127.14
Average
860.89
537.19
125.04
Standard Deviation
44.11
20.53
3.26
Coefficient of Variation
5.1%
3.8%
2.6%
Reproducibility (between day precision)
OD reading (n=3)
THP concentration (μg/mL)
QC 1
QC 2
QC 3
Day 1
829.23
535.99
132.74
Day 2
908.31
538.40
123.50
Day 3
896.10
593.43
126.57
Average
877.88
555.94
127.60
Standard Deviation
42.57
32.49
4.71
Coefficient of Variation
4.9%
5.8%
3.7%
SDS-PAGE was used to separate the urinary proteins and THP band was detected at 97 kDa (Figure
3). The relative intensity of urinary THP to standard THP
was used to estimate the concentration of urinary THP. Figure 4 shows the scatter plot of THP as measure by ELISA and SDS-PAGE where the THP
concentration by ELISA was correlated positively to that of SDS-PAGE (r =
0.648, P = 0.0004).
Figure 3
Electrophoretic mobility of commercial THP and standard THP used for THP quantification in
reference SDS-PAGE method. THP was detected at 97 kDa. Lane 1: molecular markers, lane 2
– 4: commercial THP and lane 5 – 8: urinary THP from healthy subjects
after salt precipitation.
Figure 4
The correlation between ELISA and SDS-PAGE methods in measurement of urinary THP
concentrations. The □ symbols represent an individual urine sample with its
corresponding THP concentrations as measured by the methods. The THP concentrations assayed by
ELISA method was correlated positively to SDS-PAGE (r = 0.648,
P = 0.0004). The level of significance according to Pearson correlation of
coefficient was set to alpha = 0.01.
Figure 5 shows a strong positive correlation
(r = 0.649, P = 0.0002) between THP concentrations and THP
excretions (THP/Creatinine ratio) as measured by ELISA. By using description statistic analysis,
the 95% confident interval of THP concentration in the healthy subjects was 55.00 –
77.90 μg/mL for male and 70.70 – 96.10 μg/mL for female. The THP
excretion for female healthy subjects was significantly higher (THP excretion = 12.32 ±
0.86 mg/mmol, P = 0.029) than that of their counterpart (Table 3). There was no significant difference in THP concentration
or THP excretion due to sex for stone formers. However significant differences in the THP
concentration (26.00 ± 2.2 μg/mL, P = 0.0002) and THP
excretion (4.02 ± 0.40 mg/mmol, P = 0.0001) were observed between
stone formers and healthy subjects (Table 3).
Figure 5
The correlation between THP concentration and THP excretion measured by ELISA. The
□ symbols represent an individual urine sample with its corresponding THP
concentration and THP excretion. The THP concentration was correlated positively to THP
excretion (r = 0.649, P = 0.0002). The level of significance
according to Pearson correlation of coefficient was set to alpha = 0.01.
Table 3
The average age, Creatinine concentration, THP concentration and THP/Creat ratio in healthy
subjects, stone formers and subgroup of stone formers
No. of sample
Age (Age range) (Years)
Creatinine concentration (mmol/L)
THP concentration (μg/mL)
THP/Creat ratio (mg/mmol)
Healthy subjects
117
32 (18 – 86)
8.14 ± 0.40
77.66 ± 4.68
11.23 ± 0.68
Male
41
52 (19 – 86)
9.15 ± 0.74
67.05 ± 5.97
9.25 ± 1.02
Female
76
21 (18 – 60)
7.59 ± 0.46
83.38 ± 6.37
12.30 ± 0.86ª
Stone formers
58
52 (28 – 74)
7.94 ± 0.54
26.03 ± 2.21*
4.02 ± 0.40†
Male
34
52 (36 – 74)
7.50 ± 0.67
24.56 ± 2.56
4.06 ± 0.55
Female
24
52 (28 – 68)
8.57 ± 0.88
28.10 ± 3.96
3.95 ± 0.58
Subgroup of stone formers
Staghorn calculi
39
50 (29 – 67)
8.62 ± 0.71
26.80 ± 3.02
3.86 ± 0.53
Acute renal calculi
19
55 (28 – 74)
6.55 ± 0.63
24.45 ± 2.76
4.34 ± 0.58
Footnote: All the value expressed as mean ± SE. Symbol ªindicates
significant compared with male healthy subjects, P = 0.029; * significant
compared with healthy subjects, P = 0.0002 and †
significant compared with healthy subjects, P = 0.0001.
Figure 6 shows the distribution of THP concentration
detected in healthy subjects and the stone formers. The best fit line to distinguish healthy
subjects from stone formers was found at 37.00 μg/mL and 41.20 μg/mL THP
concentrations (P < 0.05) for male and female, respectively. Using
these cut off values, the specificity and sensitivity of the assay were 80% and 86%,
respectively (Table 4).
Figure 6
Establishing of cut-off points for ELISA. The o symbols represent individual urinary THP
concentration. The horizontal line indicated cut-off values selected for ELISA. The selected
cut-off value for male was 37.00 μg/mL and for female was 41.20 μg/mL. The
number of healthy subjects and stone formers tested were 117 and 58, respectively.
Table 4
Sensitivity and specificity of the developed ELISA.
SDS-PAGE method
Quantitatively high of urinary THP
Quantitatively low of urinary THP
ELISA method
Quantitatively high of urinary THP
94
8
Quantitatively low of urinary THP
23
50
ELISA performance
Specificity = 80%
Sensitivity = 86%
Discussion
Tamm Horsfall glycoprotein has been identified as a useful urinary biomarker to determine the
formation of a kidney stone. Upon evaluation of 117 healthy subjects and 58 stone formers by the
currently developed ELISA, we found that THP can be used as a reliable biomarker for screening
of kidney stone disease. The used of THP as biomarker for kidney stone disease was verified
using SDS-PAGE, whereby a positive correlation (r = 0.648, P =
0.0004) between the SDS-PAGE and ELISA was observed. Although it is based on the common ELISA
principle, we have shown that it is a cost effective and reliable screening assay.In the preparation of the microtiter plate for capturing the urinary THP, WGA that is specific
to THP is chosen. Binding of WGA to THP is through the di N-acetylglucosamine
and sialic acid on the receptor of THP 15, however
reports had shown stone formers excreted molecular defective urinary THP that devoid of sialic
acid 10, 13 and
thus may lower the detection of THP in the stone formers by ELISA. However, since low THP
detection indicates stone formation, it will not interfere with the interpretation of positive
result for stone formation. Nevertheless, we believe that low THP in the stone formers are of
pathogenic importance and is due to a qualitative factor that is depressed synthesis or
decreased cellular secretion of THP 11, 20 rather than quantitative defect. The binding of THP to the
WGA is proportional to the amount of free THP in the urine as aggregation of THP results in
hidden binding sites. The optimum urine dilution with maximum amount of free THP was found to be
at 1:10 urine dilution. In addition, TEA buffer was found to be the best dilution buffer for the
samples, standards and QCs. Whereby it contains Triton X-100 that enhances THP dissociation and
EDTA that reduces the effects of Ca2+ chelation 14. The pH of TEA buffer at 7.5 helps to solubilize THP and keeping it in a homogenous
form 14, 21, 22. Freezing of urine sample for 24 hours prior to analysis is
required to produce consistent and reproducible results, which is agreed with those of Kobayashi
& Fukuoka 21 and Goodall & Marshall 23. Antibody is the most costly item in the development of
immunoassay based technique. Therefore, it determines the cost of the assay. In this study, we
minimized the wastage of antibody by selecting an optimum antibody dilution with the least
amount of antibody usage but sufficient to give good sensitivity of the assay. The developed
assay was validated to ensure its reliability in providing useful, consistent results 18.Previous publications have shown that calcium stone formers as a group do not have reduced
levels of urinary THP that may cause by renal obstruction and reduced renal function 24, although uric acid stone formers might 25. In this study, urine was collected from patients
irrespective of stone types whom were afflicted with partial or non obstructing stones, the data
shown that reducing of urinary THP does not correspond to the degree of renal obstruction.Urinary creatinine concentration is used as the correction factor for the effect of urine
hydration on analyte concentration 26. We used urinary
creatinine concentration to estimate daily THP excretion, which was expressed as THP/Creat
ratio. False positive samples were the main reason for reduced specificity of the assay. 20% of
the healthy subjects had low THP concentration by ELISA but was found otherwise with SDS-PAGE.
These healthy subjects were with no previous records of kidney stone disease and no symptoms of
kidney stone disease at the time when urine was collected. False positive results detected in
healthy subjects may be attributed by self-aggregation of THP molecules in acidic urine 12, 27, variation in
sialic acid content of THP 10 and reduce in THP excretion
in acidic urine 28. In contrary, 14% of the stone formers
was found to have high THP concentration by ELISA but low with SDS-PAGE, Since acidic urine may
cause aggregation of THP, we adjusted the pH of these samples to 7.4 prior to SDS-PAGE analysis
and detect no significant change in THP intensity.Despite of these exceptional cases, the rest of the healthy subjects and stone formers can be
diagnosed correctly using the currently developed assay. The assay can be effectively used as a
method for prediction of kidney stone disease, whereby the patients whom were presented with
certain clinical symptoms can be screened using this assay.The cost of assaying each sample in duplicate is approximately USD0.35 and within 5 hours, 37
samples can be assayed alongside full range standards to construct a calibration curve and 3 QCs
in each plate, whereby an analyst will be able to handle 3 plates concurrently. Furthermore,
sample preparation is relatively easy where urine sample was diluted 10 times in TEA buffer. In
view that kidney stone disease is the most common nephrolithiasic related disease, this
non-invasive ELISA method may be the answer for screening of kidney stone disease prior to
confirmation by using radiogram.
Authors: Sulabha Argade; Tony Chen; Timothy Shaw; Zoltan Berecz; William Shi; Biswa Choudhury; C Lowell Parsons; Roger L Sur Journal: Urolithiasis Date: 2015-05-03 Impact factor: 3.436
Authors: Jonathan M Street; Willem Birkhoff; Robert I Menzies; David J Webb; Matthew A Bailey; James W Dear Journal: J Physiol Date: 2011-10-24 Impact factor: 5.182
Authors: Michael G Shlipak; Yongmei Li; Caroline Fox; Josef Coresh; Carl Grunfeld; Mary Whooley Journal: BMC Nephrol Date: 2011-01-14 Impact factor: 2.388